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Erythrokeratodermia Variabilis et
Progressiva Allelic to Oculo-Dento-
Digital Dysplasia
Sabine Duchatelet1,2 and Alain Hovnanian1,2,3
Erythrokeratodermia variabilis et progressiva (EKVP) is a genodermatosis with
clinical and genetic heterogeneity, most often transmitted in an autosomal
dominant manner, caused by mutations in GJB3 and GJB4 genes encoding
connexins (Cx)31 and 30.3, respectively. In this issue, Boyden et al. (2015) report
for the ﬁrst time de novo dominant mutations in GJA1 encoding the ubiquitous
Cx43 in patients with EKVP. These results expand the genetic heterogeneity of
EKVP and the human disease phenotypes associated with GJA1 mutations. They
disclose that EKVP is allelic to oculo-dento-digital dysplasia, a rare syndrome
previously known to be caused by dominant GJA1 mutations.
Journal of Investigative Dermatology (2015) 135, 1475–1478. doi:10.1038/jid.2014.535
Clinical features of EKVP
EKVP (MIM 133200) is characterized by
the co-existence of localized or general-
ized hyperkeratotic plaques back-
ground and transient stationary or
migratory erythematous plaques
(Macfarlane et al., 1991). The hallmark
of EKVP is the continual occurrence of
transient, sharply outlined, ﬁgurate red
patches of variable intensity that fade
within a few hours or days. Approxi-
matively 50% of EKVP patients have
palmoplantar keratoderma (PPK).
Initially, two separate clinical entities
were distinguished according to the
presence of migratory or stationary
erythematous patches, deﬁning erythro-
keratodermia variabilis (Mendes da
Costa, 1925) and progressive sym-
metric erythrokeratodermia (Gottron,
1922), respectively. The observation of
both phenotypes in two sisters disclosed
that these two conditions represented,
in fact, variable expression of a single
inherited clinical entity (Macfarlane
et al., 1991). Thus, the designation
EKVP was proposed to account for the
clinical heterogeneity of the disease.
EKVP is usually inherited as an auto-
somal dominant trait, but rare auto-
somal recessive transmission has also
been reported (Gottfried et al., 2002;
Fuchs-Telem et al., 2011).
Connexins and genetic skin diseases
Gap junctions are transmembrane com-
plexes that permit the rapid exchange of
ions, secondary messengers, and small
metabolites between neighboring cells
(Mese et al., 2007). They are formed by
connexins, a multigen family of at least
21 members. Connexin proteins are
named after their molecular mass, and
their genes have been classiﬁed by
sequence similarities, deﬁning three
main groups––gap junction α (GJA), β
(GJB), and γ (GJC). Connexins consist of
four transmembrane domains with
intracellular N- and C-termini.
Connexin monomers oligomerize to
hexameric homomeric or heteromeric
hemichannels (also called connexons)
in the endoplasmic reticulum (ER) and
the Golgi apparatus, which are then
translocated into the plasma membrane.
Once expressed on the cell surface, the
hemichannel docks with a connexon of
an adjacent cell to form a channel that
is termed gap junction. Connexons can
form either homotypic (docking of two
identical connexons), heterotypic
(docking of two dissimilar homomeric
connexons), or heteromeric (docking of
two heteromeric connexons) channels
(Mese et al., 2007). These diverse
combinations of connexins create
different types of channels, each having
unique properties (ionic conductance,
permeability, sensitivity to voltage, or
pH). Of note, several connexins may also
form functional nonjunctional hemi-
channels, although their physiological
relevance remains uncertain (Pfenniger
et al., 2010). Mutations in 11 connexin
genes cause a variety of genetic dis-
orders, implicating a key role in tissue
homeostasis (Lai-Cheong et al., 2007).
Mutations in connexins have been
associated with deafness, neuropathy,
and various skin phenotypes. Several
genodermatosis have been shown to be
caused by mutations in genes encoding
connexin (Cx)26, 30, 30.3, 31, and more
rarely Cx43 (Mese et al., 2007). Speci-
ﬁcally, mutations in GJB2 encoding
Cx26 can lead to the Vohwinkel
syndrome (mutilating PPK associated
with honeycomb-like keratoderma and
starﬁsh-like keratoses and deafness, MIM
124500), the keratitis-ichtyosis-deafness
(KID) syndrome (MIM 148210), the
hystrix-like ichthyosis with deafness syn-
drome (MIM 602540), PPK associated
with deafness (MIM 148350), and the
Bart-Pumphrey (knuckle pads, leukony-
chia and sensorineural deafness) syn-
drome (MIM 149200). Mutations inGJB6
encoding Cx30 cause the Clouston
syndrome (Hidrotic ectodermal dyspla-
sia, MIM 129500), and mutations in
GJB3 and GJB4, encoding Cx31 and
30.3, respectively, have been identiﬁed
in EKVP (Common et al., 2005).
Clinical and genetic heterogeneity of
EKVP
EKVP shows considerable intra- and
interfamilial clinical heterogeneity
(Common et al., 2005). The clinical
variability observed, even in patients
from the same family, suggests the
1INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute for Genetic Diseases, Paris,
France; 2University Paris Descartes, Sorbonne Paris Cité, Paris, France and 3Department of Genetics, Necker
Enfants Malades Hospital, Paris, France
Correspondence: Alain Hovnanian, INSERM UMR 1163, Department of Genetics, Laboratory of Genetic
Skin Diseases, Imagine Institute for Genetic Diseases, 2nd Floor, 24 bld du Montparnasse, 75015 Paris,
France. E-mail: alain.hovnanian@inserm.fr
COMMENTARY
www.jidonline.org 1475
effects of modiﬁer genes, epigenetics,
and/or environmental factors.
Heterozygous mutations in GJB3 and
GJB4 were reported in EKVP patients
(Richard et al., 1998; Macari et al.,
2000). They are mainly missense muta-
tions. Recessive mutations in GJB3 have
also been identiﬁed in EKVP patients
(Gottfried et al., 2002; Fuchs-Telem
et al., 2011). However, some patients
do not carry mutations in either gene
(Richard et al., 2003; Common et al.,
2005). Of note, mutations in GJB3,
expressed in the skin, cochlea, and the
peripheral nervous system, also cause
hearing loss or neuropathy associated
with deafness (Rabionet et al., 2000).
There is no clear correlation between
phenotype and the nature and/or locali-
zation of GJB3 mutations as missense
mutations responsible for EKVP or deaf-
ness co-localize in the same domains.
Previous studies have revealed that
EKVP patients harboring GJB3 or GJB4
mutations show no clinical differences,
although circinate or gyrate lesions
were initially suggested as a speciﬁc
feature of GJB4 mutations (Richard
et al., 2003; Common et al., 2005).
The molecular and functional inter-
action between Cx31 and Cx30.3 in
gap junctions may explain the absence
of genotype–phenotype correlation and
the similarity in clinical phenotypes
between patients with GJB3 or GJB4
mutations (Plantard et al., 2003). Cx31
can also interact with Cx26, 30, 32, 43,
and 45, whereas Cx30.3 can form a
channel with Cx37, 40, and 43 (White
and Bruzzone, 1996; He et al., 1999;
Abrams et al., 2006). This expands the
possibility of distinct functional conse-
quences resulting in different hetero-
typic or heteromeric gap junctions.
In this issue, Boyden et al. (2015)
reported the identiﬁcation, by exome
sequencing, dominant de novo muta-
tions in GJA1 encoding Cx43 in three
patients with EKVP. These patients
were not phenotypically different from
patients with GJB3 or GJB4 mutations,
although enlarged porcelain-white
lunulae has not been previously
observed in EKVP. This result expands
EKVP genetic heterogeneity and the
disease phenotypes associated with
GJA1 mutations, which have been
previously identiﬁed in oculo-dento-
digital dysplasia (ODDD; see below).
GJA1 mutations in ODDD and other rare
diseases
Mutations in GJA1, encoding the ubi-
quitously expressed connexin 43, were
ﬁrst reported in nonsyndromic deaf-
ness and subsequently in ODDD
(MIM164200). ODDD is a rare pleio-
tropic genetic developmental disorder
that associates craniofacial and limb
dysmorphisms, ocular, and dental
anomalies (Laird, 2014). PPK and focal
hyperkeratosis have also been
described in rare cases of ODDD
(Paznekas et al., 2003; van Steensel
et al., 2005; Kelly et al., 2006; Vreeburg
et al., 2007; Kogame et al., 2014). More
rarely, GJA1 mutations have been
reported in craniometaphyseal dysplasia
and sudden infant death (Laird, 2014).
Most ODDD mutations are dominant
missense mutations spread through the
ﬁrst two-thirds of the protein, and more
rarely in the C-terminal domain (see
Figure 4 by Boyden et al. 2015) (Laird,
2014). Rare nonsense or small
frameshift or inframe indels have also
been reported. In particular, ODDD
mutations associated with palmoplantar
hyperkeratosis were initially identiﬁed as
truncating mutations in the C-terminal
part of the protein. Subsequent reports
described missense mutations in the ﬁrst
cytoplasmic loop and the N-terminal
part of the molecule. Thus, there is
no correlation between the localization
or nature of the mutation and the
development of keratoderma.
More generally, no speciﬁc geno-
type–phenotype correlation has been
evidenced in ODDD as individuals
carrying mutations in the same Cx43
domain can exhibit signiﬁcant differ-
ences in clinical features, although rare
reported recessive mutations lead to
more severe phenotypes.
Very recently, a GJA1 mutation was
identiﬁed in two familial cases and
one sporadic case affected with the
keratoderma-hypotrichosis-leukonychia
totalis syndrome (KHLS), a rare disorder
characterized by severe skin hyperker-
atosis, congenital alopecia, and leuko-
nychia totalis, with no additional extra-
cutaneous features (Wang et al., 2014).
Thus, mutations in GJA1 underlie
severe skin phenotypes such as KHLS
and EKVP, as well as, in a less consis-
tent manner, rare and moderate cuta-
neous features in ODDD.
Connexin mutations show no genotype–
phenotype correlation and have different
effects on gap junction biology
Connexin molecules have distinct func-
tional domains required for proper gap
junction formation and functionality.
The N-terminal domain is important in
physiological proprieties of gap junc-
tion and oligomerization (see Figure 4
by Boyden et al. 2015). The trans-
membrane domains form the pore of
the gap junction and also regulate
heteromeric channel compatibility.
The extracellular loops are important
Clinical Implications
● Erythrokeratodermia variabilis et progressiva (EKVP) has been known to
be caused by mutations in GJB3 and GJB4 genes encoding connexin (Cx)
31 and 30.3, respectively. Boyden et al. (2015) provide evidence that EKVP
can also be caused by mutations in GJA1 encoding the ubiquitous
expressed Cx43.
● Aside from enlarged porcelain-white lunulae found in the three patients
with GJA1 mutations, no obvious genotype–phenotype correlation can be
found in EKVP. In particular, EKVP shares no clinical features with oculo-
dento-digital dysplasia and shows limited overlap with the keratoderma-
hypotrichosis-leukonychia totalis syndrome, both conditions which are
also caused by GJA1 mutations.
● The co-existence of hyperkeratotic plaques with transient erythematous
plaques and no extra-cutaneous ﬁndings remains the main clinical
features of EKVP, which allows one to distinguish it from these two allelic
conditions.
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for gap junction formation (connexon-
connexon interaction) and the docking
compatibility in heterotypic chan-
nels. The cytoplasmic loop and the
C-terminal domain have a role in
channel gating but also contain motifs
for binding with other partners (Laird,
2014). The two GJA1 missense muta-
tions underlying EKVP (transmembrane
domains 1 and 4) described by Boyden
et al. (2015) and the missense mutation
causing KHLS (N-terminal domain) are
not restricted to a particular Cx43
domain, and their localization does
not differ from those identiﬁed in
ODDD. Thus, the functional conse-
quences of the Cx43 mutations on gap
junction formation and activity, rather
than the nature or the location of the
mutation in a speciﬁc domain, would
appear to determine the associated
clinical phenotype.
Biological steps possibly involved in
defective gap junction function include
impaired trafﬁcking with cytoplasmic
retention (in the ER and/or the Golgi
apparatus), reduced or abolished capa-
city to assemble into hemichannels,
and loss of gap junction activity or
enhanced channel function. In addition,
disease mechanisms may also involve
transdominant effects on other co-
expressed connexin isoforms because
of heteromeric connexons and hetero-
typic channel formation, or impaired
interaction with other partners. A direct
role of hemichannel dysfunction in
diseases has also been suggested, although
the physiological function of hemichan-
nels remains elusive (Dobrowolski et al.,
2007). Interestingly, Cx43 mutations in
ODDD have been shown to result most
often in loss of gap junction function,
despite normal localization, with impaired
or increased hemichannel activity and
more rarely impaired trafﬁcking with ER
or Golgi retention (Shibayama et al., 2005;
Lai et al., 2006; Dobrowolski et al., 2007;
Gong et al., 2007; Churko et al., 2010;
Shao et al., 2012; Laird, 2014). These
mutations have a dominant negative effect
on the wild-type counterpart (Gong et al.,
2007; Shao et al., 2012).
In contrast, the Cx43 mutation caus-
ing KHLS does not alter gap junction
function but causes a gain-of-function
in hemichannel activity (Wang et al.,
2014). KHLS presents phenotypic
overlapping with conditions caused by
GJB2 mutations (Wang et al., 2014).
Thus, a transdominant effect of KHLS
Cx43 mutations on Cx26 may also
contribute to KHLS pathogenesis.
EKVP mutations in GJA1 reported by
Boyden et al. (2015) cause Cx43
retention in the Golgi apparatus pre-
venting gap junction formation and
therefore lead to loss of channel
function as ODDD mutations. Interest-
ingly, functional interaction between
Cx43 and Cx31 or Cx30.3 has been
suggested (He et al., 1999; Schnichels
et al., 2007), and Cx43 has been shown
to interact with a number of important
structural and signaling molecules
(Herve et al., 2007). Thus, reported
EKVP Cx43 mutations may have
transdominant action on co-expressed
wild-type Cx31 or 30.3, leading to a
similar clinical phenotype as GJB3 or
GJB4 mutations. Cx43 can also interact
with Cx37, 40, 45, and 56 (Laird, 2014),
as well as with different partners such
as tight or adherens junction proteins,
kinases, and phosphatases (Herve
et al., 2007). Disruption of mutated
Cx43 interaction with these partners
may also account for variations in the
disease phenotypes associated with
speciﬁc mutations.
Thus, discrepancies between func-
tional consequences could explain the
different phenotypes associated with
these mutations.
Identiﬁcation of the functional con-
sequences of mutations on hemichan-
nel and gap junction function on their
interactions with other connexins and
partners is essential to understanding
the organ speciﬁcities and speciﬁc
phenotypes associated with different
mutations within the same connexin
gene. This information is also crucial
when considering speciﬁc pharmacolo-
gical treatments, as described recently
for Cx26 mutations in the KID syndrome
(Levit et al., 2014).
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FICZ: A Messenger of Light in
Human Skin
Deeba N. Syed1 and Hasan Mukhtar1
Photosensitization, subsequent to photon absorption by chromophores present
in the human skin, appears to be a key mechanism of UV-induced oxidative
stress. The tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ), an
aryl hydrocarbon receptor ligand, has been found to be a potent UVA
photosensitizer, effective at nanomolar concentrations. A novel addition to the
family of endogenous photosensitizers, the precise mechanism(s) through which
it mediates oxidative stress in UVA exposed skin and its response to the UVB
spectrum of the solar UV ﬂux remains unexplored. Further studies related to its
functionality in the human skin, its utility as a tool against UV-induced adverse
effects, and its role in inﬂammatory skin diseases will have the potential to open
up new avenues in the realms of human skin photobiology.
Journal of Investigative Dermatology (2015) 135, 1478–1481. doi:10.1038/jid.2015.52
A study published in this issue of the
journal sheds light on the previously
unexplored photosensitizing efﬁcacy of
6-formylindolo[3,2-b]carbazole (FICZ)
in epidermal keratinocytes. Greater
than 95% of the UV energy derived
from solar radiation incident on the
human skin comprises the deeply pene-
trating longer wavelength UVA (320–
400 nm), whereas the UVB (290–
320 nm) content on the skin varies
between 2 and 5% (Wondrak et al.,
2006). Understandably, there exists a
positive correlation between wave-
lengths and skin photon pene-
tration so that 100-fold higher photon
energy is delivered to the lower epider-
mis and upper dermis in the UVA as
compared with the UVB region
(Wondrak et al., 2006). The sub-
sequent generation of reactive oxygen
species (ROS), responsible for UV
photodamage, occurs through various
mechanisms including UV-enhanced
electron leakage from the mitochondrial
respiratory chain and remodeling of
cholesterol-rich plasma membrane rafts
of keratinocytes (Gniadecki et al.,
2002). Nonetheless, photosensitization
by endogenous non-DNA chromo-
phores present in the human skin
subsequent to photon absorption
appears to be an important mechanism
of UV-induced ROS production
(Wondrak et al., 2006). The sensitizer
chromophores after initial photon
absorption either revert to the ground
state by energy dissipation or form
highly reactive bi-radical triplet states.
The long lived triplet state of the
sensitizer serves as a key photoexcited
intermediate that induces skin photo-
damage through direct interaction with
substrate molecules such as DNA bases
(type I reaction) or activation of mole-
cular oxygen via electron or energy
transfer reactions (type II reaction)
resulting in ROS generation (Castano
et al., 2004). The superoxide radical
anions derived from these type I or II
photosensitization reactions result in
the formation of hydrogen peroxide
through spontaneous dismutation
(Castano et al., 2004). UVA has been
shown to induce the formation of cyclo-
butane pyrimidine dimers subsequent to
triplet energy transfer from excited
photosensitizers to pyrimidine bases.
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